The cannabis producer Culta on Wednesday announced the launch of its tissue culture lab program.
Often touted as the future of cannabis cultivation, tissue culture technology enables cultivators to reduce costs and improve the quality of their cannabis with consistent, disease-free, scalable cannabis clones.
Culta is the first cultivator in the state of Maryland to launch a tissue culture program to reduce costs and improve the quality of cannabis with consistent, disease-free, scalable cannabis clones.
Tissue culturing has the unique ability to revitalize genetics that have lost vigor by resetting the epigenetics of the plants, which typically change after generations of traditional cloning methods. In addition, it allows cultivators to store all of their genetics in a small area and reduce the risk of pests without having to rely on chemicals.
For decades, tissue culture has been used for large-scale propagation in the agriculture industry, but the cannabis cultivation market is beginning to shift toward using the technology. Culta is the first cultivator in Maryland to have a tissue culture lab program, and the MMCC is basing some of their rules off Culta’s program. Not only does the lab act as a bank to back up their strains, but the program provides Culta with the flexibility to rotate strains in and out of production without having to house or maintain large mother plants.
Currently, Culta has 26 different strains cultured. It expects to have all their genetics stored in the lab by the end of the year and hopes to start producing new mothers from tissue cultured plants within the next few months. Long term, CULTA plans on using the tissue culture lab for breeding purposes before moving onto more advanced applications of tissue culture.